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Introduction
The number of candidates added to the transplant wait 
list continues to grow. In 2019, 8,896 liver transplants 
were performed in the United States (US) and the rate 
has been gradually increasing over the last decade (1). 
The current annual transplant rate of adult candidates 
actively listed on the wait list is 58.7% in the US and 
has increased incrementally compared to previous years. 
Current 1-, 3- and 5-year survival rates are 91.8%, 83.8% 
and 76.1%, respectively, and liver transplantation (LT) is 
being considered for a growing list of conditions evident by 
the expanding recipient pool and waiting lists. Despite the 
benefits of LT, the scarcity of organs is a universal concern 
and there have been several attempts by the transplant 
community to propose strategies to overcome the deficit. 
This has led to the consideration of livers which were 
previously considered unsuitable for transplantation and 
efforts to optimize “marginal” organs using innovative 
machine technology. We, herein, provide a brief overview 
of the existing approaches by the transplant community to 
expand the donor and recipient pool for LT.
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Extended criteria donation to increase the donor 
pool
The disparity between supply and demand has led to 
the consideration of extended criteria donor (ECD) 
liver allografts or “marginal donors” which do not meet 
the traditional criteria for organ donation. The aging 
population, longer life expectancy rates and the rising 
incidence of several metabolic conditions such as obesity, 
diabetes and fatty liver disease are all important factors 
contributing to poor donor quality. Such issues are projected 
to decrease donor liver utilisation rates from 78% to 44% if 
ECDs are not included in the pool (2). While these organs 
were previously avoided due to the fear of primary non-
function (PNF) or delayed graft function (DGF), they are 
now increasing used with the goal of improving access 
to transplantable organs (3). The underlying concern is 
the graft’s susceptibility to ischemia/reperfusion during 
the transplantation process, adding to graft dysfunction 
and poor regeneration (4). Despite this risk, ECDs have 
played an important role in expanding the donor liver pool 
with compelling evidence demonstrating their ability to 
reduce wait list mortality and exhibit recipient outcomes 
comparable to standard liver donations (5,6). There is 
no universally accepted definition for what constitutes an 
ECD, however, frequently cited characteristics are advanced 
donor age, donation after cardiac death (DCD), hepatic 
steatosis, split liver transplantation (SLT), and donors with 
an infectious risk or previous malignancy (3,7,8). 
Accepting donors with an advanced age
The use of livers from older donors is becoming more 
frequent in modern practice, despite the concern of DGF 
during the immediate post-operative period (7,9,10). No 
clear age cut-off exists and several transplant units are 
expanding that which is considered an acceptable donor age 
in an effort to match the increased demand to the ageing 
population demographic and available donor pool (11). 
In 2014, 8% of liver donors from the US were 65 years and 
older and this group increased further to 10% in recent 
Organ Procurement and Transplantation Network (OPTN) 
data (12,13). In a report from the European Liver Transplant 
Registry, Adam et al. observed that 29% of donors were 
older than 60 years and 11% were 65 years or older (14). 
Some studies have reported acceptable outcomes in livers 
from older donors. In an early study by Zapletal et al. 
comparing liver allografts from donors both older and 
younger than 80 years, comparable results were achieved 
in the postoperative course and older livers grafts were 
functionally stable at discharge (15). Several other units 
mirrored similar results in liver allografts from donors over 
60 years and in some studies favourable outcomes were 
achieved from donors older than 70 years as the transplant 
community continues to explore an acceptable upper age 
limit (16-18). In a recent study using the United Network 
for Organ Sharing (UNOS) database, Haugen et al. 
reported a significantly lower 5-year cumulative mortality 
rate for patients who accepted livers from donors >70 years 
when compared to a matched control group who declined 
the same offer (23% vs. 41%) and the authors demonstrated 
a substantial long-term survival benefit in the former 
group (19). Despite these favourable outcomes, judicious 
matching of older donors is paramount as these grafts are 
more susceptible to ischemia reperfusion injuries, biliary 
complications, a slight preponderance for hepatic artery 
thrombosis and the risks are particularly heightened in 
donors with hepatitis C (17,20,21).
Increasing DCD
Livers from donors with irreversible brain injury, not 
meeting the criteria for brain death, have resulted in the 
expansion of the donor pool. A study by Saidi et al. reported 
an increase in the utility of DCD organs from 4.9% to 
11.7% during a 10-year study period (22). In the case of 
LT, recent OPTN data suggests an increase from 4.8% to 
6.9% in DCD livers between 2008 and 2018 (12). Several 
studies comparing DCD livers with standard brain-dead 
donors (DBD) have demonstrated poorer allograft and 
patient survival rates in the latter. This is likely related to 
the longer ischemia time associated with DCD donors, 
commencing from the time of extubation until cold 
perfusion, which can be highly variable. A large multicentre 
study of 2,572 liver transplants comparing DCD and DBD 
livers identified that 3-year graft loss and recipient mortality 
were twice as high with DCDs (23). In contrast, a study by 
Taner et al. noted no differences in 1-, 3- and 5-year patient 
survival rates between DBD and DCD groups and similar 
comparable outcomes for graft survival (24). In an effort to 
determine factors leading to graft loss, the authors identified 
a link between the asystole to cross clap duration and the 
development of ischemic cholangiopathy, an important and 
feared consequence of DCDs. Nonetheless, DCDs can 
significantly and safely expand the donor pool when used 
with caution, adhering to a warm ischemia time less than 
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30 minutes, using donors younger than 50 years and limiting 
cold ischemia time (7,8). Future efforts to minimize ischemia 
times and expand the upper age cut-off will further increase 
the utility of DCD livers and expand the donor pool.
The use of steatotic livers
The rising incidence of obesity and metabolic syndromes 
has led to the commensurate rise in non-alcoholic fatty liver 
disease (NAFLD), with a population prevalence of up to 
30% in Western societies (25,26). These rising incidences 
and prevalence rates have seen parallel increases in potential 
donors with hepatic steatosis. Traditionally, steatotic 
allografts were avoided in LT for posing significant clinical 
challenges in terms of early graft dysfunction and PNF. An 
early study by Spitzer and colleagues analyzing a large US 
registry of transplant recipients conclusively established 
that livers with 30% or greater macrovesicular steatosis 
were associated with lower 1-year survival rates (27). 
Similar studies have demonstrated unfavourable outcomes 
in the use of grafts with moderate (30–60%) and severe 
(>60%) steatosis, largely due to the increased susceptibility 
of steatotic grafts to ischemia reperfusion injuries (28,29). 
However, in an effort to further expand the donor pool, 
fatty livers are increasingly considered for transplantation 
and form a major component for ECDs. In well matched 
cases, mild steatosis may have a minimal impact on 
reperfusion injury and post-transplant hepatic functionality. 
A study by Dutkowski and colleagues analysed both US 
and European liver transplant registries and determined 
grafts with microvesicular and 30% or less macrovesicular 
steatosis can be used safely with outcomes comparable to 
non-steatotic livers (30). Acceptable outcomes were also 
achieved in steatosis greater than 30% with careful risk 
adjustment, although this remains controversial. Similar 
studies assessing the suitability of steatotic grafts have 
also considered the use of moderate to severely steatotic 
allografts with somewhat acceptable post-transplant 
outcomes, provided they are supplied by low-risk donors 
(31,32). Continuing to extend the upper limits of steatosis 
and define the acceptability of steatotic grafts will still be a 
matter for debate, however, the integration of these grafts 
into the donor pool has been a key element in providing 
more livers for transplant. 
Considering donors with an increased infectious risk
The use of donors with exposure to hepatitis B (HBV) or 
C (HCV) virus has been more acceptable in current times, 
albeit previously met with strong objection due to initial 
concerns regarding the introduction of aggressive viral 
strains to immunosuppressed recipients. In the context of 
HCV, there has been a shift in previous attitudes and recent 
OPTN data reports an increase in the number of livers 
recovered from hepatitis C positive donors and the number 
of wait-list candidates willing to accept these livers (12). 
Rigorous matching remains pertinent and younger donors 
are preferred due to the fear of increased fibrosis in 
recipients when older HCV positive donors are used (33). 
Hepatitis C positive recipients transplanted with positive 
donors have demonstrated comparable outcomes to those 
receiving HCV negative livers (34,35). In an effort to 
further expand the donor pool for all patients, transplanting 
HCV positive livers into HCV negative patients, with 
the addition of effective antiviral regimens, has seen some 
promise in terms of long-term outcomes. Chhatwal and 
colleagues report compelling evidence demonstrating that 
accepting HCV positive livers for all donors may increase 
life expectancy and decrease wait-list mortality (36). 
Additionally, a recent study by Cotter and colleagues 
analysing data from 2008 to 2018 reports increased 3-year 
graft survival rates from 79% to 88% in HCV negative 
donors receiving HCV positive livers and direct-acting 
antiviral therapies (37). Similarly, the increased use of 
organs from HBV positive donors has the potential to 
expand the donor pool. In a study by Cholongitas and 
colleagues, recipients without prior exposure to HBV 
receiving antiviral prophylaxis showed excellent outcomes 
following transplantation with HBV positive livers (38). 
Effective HBV prophylaxis in the form of hepatitis B 
immunoglobulin or oral antiviral therapy have led to a 
reduction in HBV transmission and viral recurrence in 
select donors and some units have included these in their 
donor pool (39-41). While this practice is still limited to a 
few centres because of the concern of viral reactivation in 
recipients, more effective prophylaxis could encourage the 
inclusion of such grafts for the wider recipient pool.
Split liver grafts
Splitting livers (SLT) into two potential grafts has been 
explored as another method to increase donor supply, 
however, their use has been relatively stable over the last 
decade (12). This procedure usually involves donating 
the left lateral segment to a pediatric recipient and 
transplanting the right trisegment into an adult, although 
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splitting the liver into a right and left lobe for two adults 
has also been described (7,42). It has been estimated that 
up to 20% of livers are suitable for splitting, however, 
the technique is limited to specialist centres due to the 
complexity of the procedure and the heightened risk 
of biliary and vascular complications (42,43). A study 
by Vagefi and colleagues assessing outcomes in SLT 
recipients reported 93%, 77%, and 73% and 89%, 76%, 
and 65% overall patient and graft survival rates at 1-, 5- 
and 10-years (44). A similar study by Doyle and colleagues 
demonstrated 95.5%, 89.5% and 89.5% 1-, 5- and 10-year 
survival rates in adults recipients of SLT, comparable 
to whole organ (WLT) recipients (45). In contrast, a 
multicentre study by Aseni demonstrated lower 5-year 
survivals in patients receiving SLT compared to WLT 
(63.3% vs. 83.1%) (46). While SLT continues to be limited 
to centres with technical expertise, they require high quality 
grafts to gain acceptable post-operative outcomes and 
currently only represent 1% of US liver transplants and 6% 
of transplants in Europe (12,47).
Living donor LT (LDLT)
First reported in the US in 1998, LDLT is an additional 
mechanism to expand the donor pool and increase 
organ availability. Both right and left lobes can be used 
in transplantation with the latter generally reserved for 
small sized recipients and paediatric patients. A left lobe 
resection has the added benefit of removing a smaller 
portion of liver from the living donor. By contrast, the 
right lobe, mainly reserved for adult patients, accounts for 
up to two-thirds of the total liver mass and can potentially 
cause significant harm to the donor if the remnant liver 
volume is too small or unhealthy to support the metabolic 
and physiological needs of the recipient. The number of 
LDLTs has increased slowly over the past 2 decades and 
recent US liver registry data reports LDLTs accounted for 
up to 4.4% of liver donations in 2018 (12,48). Although 
modest, the increase in LDLTs has been largely driven 
by a rise in the number of unrelated directed donors (12). 
The number of left lobe resections has also decreased 
corresponding with a parallel rise in right lobe donations. 
A study by Shah and colleagues demonstrated significantly 
shorter mean waiting times between right lobe donations 
and patients awaiting grafts from deceased donors (49). 
Although LDLT has the advantage of optimizing the timing 
of surgery, comprehensive donor work-up and minimizing 
cold ischemia and organ transport times, the process still 
poses a risk to the donor and can subject a healthy person 
to a substantial burden (50). Overall donor mortality rates 
range from 0.2% to 0.8% with some studies reporting a 
slight donor survival benefit in right lobe donations (51-53). 
Graft failure is reported to occur in up to 7.8%, 14.6% and 
26.5% of LDLTs at 1, 3 and 5 years with more favourable 
outcomes demonstrated in non-hepatocellular carcinoma 
(HCC) diagnoses and Model for End-stage Liver Disease 
(MELD) scores less than 20 (12). Furthermore, a study by 
She and colleagues reported, in an analysis of 218 patients, 
significantly better 5-year graft survival rates in using 
right lobe LDLT, albeit comparable 5-year patient survival 
rates (54). These findings were contrasted by Olthoff and 
colleagues who in a large multicentre study of 963 LDLTs 
demonstrated similar graft survival rates in right and left 
lobe LDLTs with decreasing rates of graft failure associated 
with greater centre experience (55). However, despite these 
promising results several studies have reported inconsistent 
graft survival rates between LDLT and standard cadaveric 
liver donations. Some analyses have demonstrated decreased 
graft survival rates in LDLT (56,57), while more recent 
studies appear to demonstrate similar long-term 10-year 
survival rates between patients receiving grafts from 
living donors and deceased donor grafts (55). For this 
reason, LDLT is reserved for high volume centres with 
specialist expertise due to the complexities of the procedure 
which requires a deep understanding of the physiological 
requirements of the graft to ensure sufficient hepatic 
regeneration and minimize donor risk. 
Machine perfusion to optimise liver quality
The recent arrival of ex-vivo machine perfusion techniques 
is beginning to change the landscape of how “marginal” 
livers are utilized and has the potential to fully expand the 
donor pool and reduce liver discard. Hypothermic and 
normothermic machine perfusion technologies have shown 
promising results in minimising injury to DCD grafts and 
steatotic livers (58,59). Schlegel and colleagues provided 
5-year outcome data on patients receiving DCD liver 
transplants following treatment with hypothermic oxygen 
perfusion prior to transplantation. Outcomes of treated 
DCD livers were similar to DBD and superior to untreated 
DCDs with significantly less graft loss events (58). A recent 
study reported similar encouraging results in transplanting 
previously rejected liver allografts following the application 
of normothermic machine perfusion (60). While the 
optimal temperature setting continues to be debated, this 
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innovation may salvage various extended criteria allografts 
and modify their risk for routine use, ultimately expanding 
the donor pool.
Expanding the recipient pool
Despite several strategies attempting to increase the liver 
donor pool, the recipient pool continues to expand and 
wait list mortality remains a concern. The wider acceptance 
of LT and improved outcomes has allowed clinicians to 
consider transplanting patients they were historically 
reluctant to do so. According to OPTN data, alcoholic 
liver disease, non-alcoholic steatohepatitis (NAFLD) and 
HCC are the most common conditions leading to LT in the 
US and the increased public burden of these diseases has 
contributed to an increased number of patients requiring 
transplantation (12). The healthcare prevalence of alcoholic 
liver disease continues to grow. A study by Jinjuvadia and 
colleagues observed a substantial increase in the number of 
alcohol-related hospitalizations over an 8-year period (61). 
In 2018, the proportion of candidates listed for ALD 
increased considerably from 22.7% to 29.8% over a 10-year 
period (12). Similarly, NAFLD is becoming more prevalent 
and has been linked with the alarming growth rate of 
population obesity (26). Several models have projected 
this to become the leading cause for LT as more patients 
progress to decompensated cirrhosis warranting curative 
intervention. In addition, global trends have demonstrated 
a rising incidence in the diagnosis of HCC, although the 
causes of this are still unclear (62). The evidence regarding 
transplanting HCC patients, particularly since the 
introduction of the Milan criteria, has been promising for 
unresectable disease and more patients are being considered 
for LT and form a substantial portion of the recipient pool 
(63,64). The proportion of HCC candidates awaiting LT 
increased from 3.4% to 9.8% between 2008 and 2018 (12). 
There has been some interest in expanding the current 
eligibility guidelines for HCC. Yao and colleagues report 
similar LT outcomes in HCC patients with tumours as 
large as 6.5 cm or less than 4 nodules smaller than 4.5 cm 
and a total tumour diameter less than 8 cm, arguing that the 
current Milan staging is too restrictive (65). Additionally, 
the success of chemotherapy has seen several patients with 
advanced disease downstaged to liver disease within the 
Milan criteria and meeting eligibility for LT (66). Several 
other hepatic tumours have been added to the recipient pool 
with promising results in some units. In a small prospective 
case-series by Lunsford and colleagues, patients with locally 
advanced intrahepatic cholangiocarcinoma and stable 
disease from neoadjuvant therapy had 1-, 3- and 5-year 
survival rates of 100%, 83.3%, and 83.3% respectively. 
While the study only involved a small selected group of 
patients, LT showed promise (67). In addition, despite 
initial reluctance, some units have started to reconsider 
LT for colorectal liver metastases (CLM). In a study 
comparing LT and chemotherapy for nonresectable CLM, 
LT observed better 5-year survival rates (56% vs. 9%) (68). 
Although, this has yet to gain widespread acceptance, 
better expertise in LT and cancer biology could see a rapid 
expansion in the recipient pool and the inclusion of patients 
who were previously contraindicated for LT.  
Future directions
The transplant community continues to evolve and active 
efforts to expand both the donor and recipient pools are 
in constant motion. LT remains a curative option for a 
wide spectrum of the population and expertise in surgical 
technique, immunotherapy and post-operative care are 
among the several elements underpinning the continually 
improved outcomes reported internationally. While 
breakthroughs in machine perfusion and chemotherapy 
are still underway, the role of social media in increasing 
awareness of organ donation may be a feasible route. Kumar 
and colleagues, in collaboration with Facebook, created 
a mobile application whereby waitlisted candidates were 
allowed the opportunity to create a post and communicate 
their experience with organ failure and the need for live 
organ donation (69). Impressively, candidates who engaged 
with the app were 6.6 times more likely to have a donor 
come forward compared with matched controls and the 
app was received well overall (69). As the boundaries of 
social media platforms continue to push limits, some have 
advocated for the increased use of social media billboard 
approaches and targeted campaigns to shift societal 
perspectives of organ donation and gain public attention (70).
Conclusions
In summary, LT is a growing field with boundless potential. 
The disparity between patients who need a liver transplant 
and those who receive one is a constant concern, and while 
significant progress has been made in the field, further 
efforts from the national and international consortia are 
warranted. Pre-existing criteria for LT and recipient 
boundaries are continually challenged and expanded and, 
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when coupled with judicious matching and careful patient 
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